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MRE11–RAD50–NBS1 protein complexMps one binder proteins (MOBs) are conserved regulators of essential signalling pathways. Biochemically,
human MOB2 (hMOB2) can inhibit NDR kinases by competing with hMOB1 for binding to NDRs. However, bio-
logical roles of hMOB2 have remained enigmatic. Here, we describe novel functions of hMOB2 in the DNA dam-
age response (DDR) and cell cycle regulation. hMOB2 promotes DDR signalling, cell survival and cell cycle arrest
after exogenously inducedDNAdamage. Under normal growth conditions in the absence of exogenously induced
DNA damage hMOB2 plays a role in preventing the accumulation of endogenous DNA damage and a subsequent
p53/p21-dependent G1/S cell cycle arrest. Unexpectedly, these molecular and cellular phenotypes are not ob-
served upon NDR manipulations, indicating that hMOB2 performs these functions independent of NDR signal-
ling. Thus, to gain mechanistic insight, we screened for novel binding partners of hMOB2, revealing that
hMOB2 interacts with RAD50, facilitating the recruitment of theMRE11–RAD50–NBS1 (MRN) DNA damage sen-
sor complex and activated ATM to DNA damaged chromatin. Taken together, we conclude that hMOB2 supports
the DDR and cell cycle progression.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
The family of Mps one binder (MOB) proteins is highly conserved
from yeast to humans [1]. Yeast expresses two MOB proteins, the Dro-
sophila genome encodes three different MOBs, termed dMOBs, and
mammalian genomes encode at least six different members (MOB1A,
MOB1B, MOB2, MOB3A, MOB3B, MOB3C), indicating a functional diver-
siﬁcation of MOBs from unicellular to complex multicellular organisms
[1]. In yeast, Mob1p and Mob2p are required for mitotic exit and cell
morphogenesis through regulation of the conserved NDR/LATS kinases
Dbf2p and Cbk1p [2–4]. In ﬂies dMOB1 (also termed Mats) functions
as an essential tumour suppressor together with Warts/Lats kinase
[5–7], while dMOB2 has reported roles in neuromuscular junctions [8]
and photoreceptors [9] that might be regulated by the association of
dMOB2with Tricornered [10], the ﬂy counterpart of humanNDR kinases
[11]. dMOB1 and dMOB3 can also genetically interact with Tricornered
[10]. However, the biological roles of dMOB3are yet to be deﬁned inﬂies.f2-related; LATS, Large tumour
50-NBS1;IR, Ionizingradiation;
mutated; PIF, PDK1-interacting
sity College London, 72 Huntley
7679 0723.
ll. Signal. (2014), http://dx.doIn mammals, the tumour suppressive role of MOB1 as a LATS regula-
tor is conserved [5,12,13]. Signiﬁcantly, MOB1-deﬁcient mice [14] de-
velop a broader range of tumours as reported for loss of LATS kinases
[5], suggesting that MOB1 performs important biological functions in-
dependent of LATS signalling. Perhaps this involves the interaction of
MOB1 with NDR kinases, since MOB1 can interact with NDR kinases
through a domain conserved between LATS and NDR kinases [13,15].
In contrast, although MOB2 binds to this same domain, MOB2 can
only associate with NDR, but not with LATS kinases [16–18]. Currently,
NDR kinases are the only reported binding partners of hMOB2 [1].
hMOB2 competes with hMOB1 for NDR binding [18], hence the
hMOB1/NDR complex is associated with increased NDR activity [19],
while hMOB2 binding to NDR blocks NDR activation [18]. In contrast,
hMOB3 neither associates with NDR nor LATS [18], but rather interacts
with the pro-apoptotic kinaseMST1, thereby negatively regulating apo-
ptotic signalling in glioblastoma multiforme [20]. Therefore, mammali-
an MOB1 and MOB3 have been attributed tumour suppressive or
oncogenic roles, respectively. However, although the human MOB2
gene appears to display loss of heterozygosity (LOH) in more than 50%
of bladder, cervical, and ovarian carcinomas (The Cancer Genome
Atlas, TCGA) [21], any deﬁned physiological cancer-related functions
of mammalian MOB2 have yet to be described. So far, it has only been
reported thatMOB2 can contribute tomorphological changes inmurine
neurites and rat astrocytes [22,23].i.org/10.1016/j.cellsig.2014.11.016
2 V. Gomez et al. / Cellular Signalling xxx (2014) xxx–xxxA recent genome wide screen for novel players in the DNA damage
response (DDR) identiﬁed hMOB2 (also termed HCCA2) as one of
many candidates awaiting validation of their potential role in the DDRFig. 1. hMOB2 promotes cell survival and G1/S cell cycle arrest in response to exogenously induc
cells transiently transfected for 24 h with indicated siRNAs. (B, C) Clonogenic survival of U2-O
doxorubicin or ionising radiation (IR). Quantiﬁcations are shown as percentage of colonies fo
plating efﬁciencies of the corresponding untreated controls. P-values are: 50 nM = 0.037, 10
0.035. (D) Immunoblotting with indicated antibodies of MCF10A cell lysates from pSuper.retr
pools treatedwith indicateddoxorubicin doses, before release in drug-freemedium for indicated
ofMCF10A cells in the G1 cell cycle phase (n=3). Control (shLuc), hMOB2-depleted (shMOB2)
P-values are: 8 h = 0.397 (ns, not signiﬁcant), 24 h = 0.027, 48 h = 0.011.
Please cite this article as: V. Gomez, et al., Cell. Signal. (2014), http://dx.do[24]. To date, direct or indirect functions in the DDR have not been de-
scribed for any MOB2 family member. Therefore, considering that the
DDR is critical to maintain genomic integrity and to prevent ageinged DNA damage. (A) Immunoblottingwith indicated antibodies of U2-OS cell lysates from
S cells upon hMOB2 knockdown (siMOB2) compared with controls (siCTL) in response to
rmed after treatment with indicated doses (n = 4). Results were corrected according to
0 nM = 0.018, 250 nM = 0.029, 500 nM = 0.231; 1 Gy = 0.039, 2 Gy = 0.005, 3 Gy =
o.puro infected cells expressing indicated shRNAs. (E) Cell cycle analysis of MCF10A cell
time points. Representative time courses are shown. (F)Histograms showing percentages
, p53-depleted (shp53), and hMOB2/p53 co-depleted (shp53/MOB2) cells were compared.
i.org/10.1016/j.cellsig.2014.11.016
Fig. 2. hMOB2 supports IR-induced ATM-NBS1-SMC1 signalling. (A) Phosphorylation of ATM and ATM substrates analysed by immunoblotting with indicated antibodies of RPE1 cell ly-
sates from cells transiently transfected for 24 h with indicated siRNAs (−, siCTL; +, siMOB2). Cells were treated with indicated ionising radiation (IR) doses, before processing for immu-
noblotting. (B) Graphs showing the kinetics of ATM activation as judged by Ser1981 auto-phosphorylation and substrate phosphorylations by ATM obtained by densitometry
quantiﬁcation of Western blots shown in A (phosphorylated/total proteins).
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4 V. Gomez et al. / Cellular Signalling xxx (2014) xxx–xxxand tumourigenesis [25], we decided to investigate on the cellular and
molecular level whether hMOB2 is a DDR protein. Here, we show that
hMOB2 promotes cell survival, cell cycle checkpoint activation, and
DDR signalling upon exogenously induced DNA damage. Under normal
growth conditions in the absence of exogenously induced DNA damage
hMOB2 loss causes the accumulation of DNA damage, triggering a
p53/p21-dependent G1/S cell cycle arrest not phenocopied by NDRma-
nipulations. Thus, to gain mechanistic insights, we screened for novel
binding partners of hMOB2, discovering that hMOB2 interacts with
RAD50, a key component of the essential MRE11–RAD50–NBS1
(MRN) DNA damage sensor complex [26–28]. hMOB2 supports the re-
cruitment of MRN and activated ATM to DNA damaged chromatin,
thereby providing the ﬁrst mechanistic insight into why hMOB2 can
play a role in DDR signalling, cell survival, and cell cycle checkpoints
after DNA damage induction.2. Materials and methods
2.1. Cell culture, chemicals, drug treatments, and transfections
RPE1-hTert, COS-7, PT67 andU2-OS cells weremaintained in DMEM
supplemented with 10% foetal calf serum (FCS). BJ-hTert ﬁbroblasts
were grown in DMEM:Medium199 (4:1) supplemented with 10% FCS
and gentamicin (50 μg/ml).MCF10A cells weremaintained as described
[29]. Blasticidin, zeocin, puromycin (Invivogen), and G418 (PAA Labora-
tories) were used as reported [30]. Exponentially growing cells were
plated at a consistent conﬂuence and transfected with siRNAs and plas-
mids using Fugene 6 (Promega), Lipofectamine RNAiMax (Invitrogen),
or Lipofectamine 2000 (Invitrogen) according to the manufacturer's in-
structions. Tetracycline (Sigma) was used as described [30]. Doxorubi-
cin (Sigma) was added as indicated. For drug washout experiments,
cells were washed three times with complete media without drug and
allowed to recover in complete medium without drug. All siRNAs
were from Qiagen and sequences are available upon request.2.2. Generation of stable cell lines and IR treatments of cells
Tetracycline-inducible (Tet-on) cell lines were generated and main-
tained as described [30]. Brieﬂy, RPE1 hTert Tet-on cells [30] were
transfected with pTER constructs [31] expressing shRNAs against
NDR1 or hMOB2, or pT-Rex-HA-NDR1-PIF plasmid, and selected as de-
scribed [30]. Retroviral pools using pMKO.1 puro, pSuper.retro.puro, or
pLXSN plasmids were generated as reported [32]. For IR treatments,
cells were seeded at ﬁxed densities, followed by irradiation with indi-
cated doses at a rate of 5 Gy/min (215 kV, 12.0 mA, 1.0 mm Al ﬁlter)
using an AGO HS 320/250 X-ray machine (AGO X-ray Ltd.) equipped
with a NDI-321 stationary anode X-ray tube (Varian), and then proc-
essed for immunoblotting, clonogenic, or comet assays as described
below.2.3. Yeast two-hybrid (Y2H) screen
To identify novel direct hMOB2 binding partners, a normalised
universal human tissue cDNA library was screened using pLexA-N-
hMOB2(full-length) as bait. The complexity of the pGADT7-recAB
based cDNA library was 2.8 × 10E6 with an average insert size of
1.58 kb. Screening of 1 × 10E6 transformants yielded 59 bait dependent
hits, resulting in the identiﬁcation of total 28 putative interactors. Only
four novel binding partners of hMOB2 were identiﬁed at least twice
(RAD50, UBR5, KPNB1, and KIAA0226L). All nine hits for UBR5 were
out of frame and identiﬁed the HECT domain of UBR5 as potential inter-
action site, while all four hits for RAD50were in frame (see Supplemen-
tary Table S1). The Y2H screen was performed by Dualsystems Biotech
AG (Zurich, Switzerland).Please cite this article as: V. Gomez, et al., Cell. Signal. (2014), http://dx.do2.4. Immunoblotting, immunoprecipitations, chromatin isolation, and
densitometry analysis
Immunoblotting and co-immunoprecipitation (co-IP) were done as
described [32,33]. For chromatin–cytosol separations, cells were har-
vested with ice-cold PBS, centrifuged for 2 min at 1000 ×g at 4 °C, and
resuspended in buffer A (10 mM Pipes, 100 mMNaCl, 300 mM sucrose,
3 mM MgCl2, 5 mM, EDTA, 1 mM EGTA, 50 mM NaF, 0.1 mM Na3VO4,
0.1% Triton X-100, 1 mM benzamidine, 4 μM leupeptin, 0.5 mM PMSF
and 1 mM DTT at pH 6.8). Lysates were incubated for 10 min and then
centrifuged for 5 min at 1300 ×g at 4 °C. Supernatants were collected
as cytosolic fraction. Pellets were washed once with buffer A, lysed
for 10 min at 4 °C in buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM
benzamidine, 4 μM leupeptin, 0.5 mM PMSF and 1 mM DTT at pH 8.0),
followed by centrifugation for 5 min at 1700 ×g at 4 °C. Supernatants
(soluble nuclear fraction) were discarded. Pellets (insoluble chromatin
fraction) were washed once with buffer B, resuspended in Laemmli
buffer and fragmented using a 26GMicrolanceG needle (BD). Equal vol-
umes of fractions were analyzed by immunoblotting. Densitometry
analysis of immunoblots was performed using the ImageJ software
(NIH).
2.5. Antibodies (generation and sources)
Rat polyclonal anti-hMOB2 antibodies were raised against puriﬁed,
bacterially produced full-length hMOB2 fused C-terminally to GST
protein. Rat injections/bleed collections were done by Eurogentec.
Anti-protein antibody was puriﬁed by pre-absorbing the bleeds against
10mgof immobilisedGST and then binding to 10mgofmaltose binding
protein (MBP)-hMOB2 coupled to amylose beads (New England
Biolabs). Antibodies were eluted with 0.2 M glycine (pH 2.5). Anti-HA
12CA5, anti-myc 9E10 and anti-NDR2 antibodies have been described
[34,35]. All antibodies are listed in Supplementary Table S2.
2.6. Immunoﬂuorescence microscopy
Cells were processed for immunoﬂuorescence as deﬁned [32,33].
Images were acquired with an ApoTome ﬂuorescence microscope
(Zeiss) and processed with AxioVision AxioVS40 V4.8.1.0 (Zeiss) and
Photoshop CS5 (Adobe Systems Inc.).
2.7. FACS cell cycle and cell proliferation analyses
For FACS analysis of DNA content cells were processed as deﬁned
elsewhere [32], before analysis using a CyAn ADP Flow Cytometer
(Beckman Coulter). Cell cycle proﬁles were analyzed with Summit
(Beckman Coulter) and FlowJo (Tree Star) softwares. For cell prolifera-
tion analysis, cells were seeded at deﬁned densities in triplicates. For
experiments involving Tet-on cell lines, fresh tetracycline was added
the day of seeding. At indicated time points, the number of viable
cells was determined by trypan blue exclusion using the automated
ViCell-XR cell counter (Beckman Coulter).
2.8. Comet assays
Single cell gel electrophoresis (comet) assays were performed as de-
scribed [36]. After electrophoresis individual cells were visualised using
an inverted microscope (Nikon) and analysed using Komet Analysis
software 4.02 (Andor Technology). Per sample/time point/experiment
at least 100 cells were randomly selected fromduplicate slides and indi-
vidual DNA damage levels were determined.
2.9. Clonogenic survival assays
Clonogenic assays were performed as described [37]. Brieﬂy, cells
were seeded at predetermined densities in six-well plates and allowedi.org/10.1016/j.cellsig.2014.11.016
Fig. 3. hMOB2 is required for cell cycle progression. (A) Immunoblotting with indicated antibodies of RPE1 Tet-on shMOB2 cell lysates after incubation of cells with (+Tet) or without
(−Tet) tetracycline as indicated. (B) Proliferation rates of three independent RPE1 Tet-on shMOB2 clones (n = 3; P-value = 0.0012). (C) Cell cycle analyses of RPE1 Tet-on shMOB2
cells at indicated time points with (+Tet) or without (−Tet) of tetracycline. Percentages of cells in each cell cycle phase are shown (n = 3). (D) RPE1 Tet-on shMOB2 cells with
(+Tet) or without (−Tet) tetracycline were serum starved for 72 h, washed twice, released in medium containing 20% FCS, and processed for cell cycle analysis at indicated time points.
(E) Histograms showing the percentage of synchronised cells in each cell cycle phase (n=3). (F) Immunoblottingwith indicated antibodies of cell lysates obtained from synchronised cell
cultures described in D.
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followed by three media washes. Cells were replenished with fresh
complete medium every 3 days until colony size reached more thanPlease cite this article as: V. Gomez, et al., Cell. Signal. (2014), http://dx.do50 cells per colony. Then cells were ﬁxed with MeOH/acidic acid (3:1)
solution for 5 min, followed by staining with 0.5% crystal violet
(Sigma) for 15 min. The surviving fraction was calculated usingi.org/10.1016/j.cellsig.2014.11.016
7V. Gomez et al. / Cellular Signalling xxx (2014) xxx–xxxthe plating efﬁciencies of the corresponding non-treated controls as
reference.
2.10. Construction of plasmids
hMOB2 and NDR1/2 cDNA and shRNA plasmids were described [18,
19,32]. pT-Rex-HA-NDR1-PIF was generated by inserting HA-NDR1-PIF
[38] into pT-Rex-DEST30 (Invitrogen) using Gateway technology
(Invitrogen). The RAD50 cDNA was ampliﬁed by PCR and subcloned
into pcDNA3_HA using BamHI and XhoI. pCMV-FLAG-UBR5 full-length
was kindly provided by R. Sutherland (Garvan Institute of Medical
Research, Sydney, Australia), and used as a template to amplify the
HECT domain (residues 2501 to 2799), which was subcloned into
pcDNA3_HA using BamHI and XhoI. pMKO.1 puro shGFP (10675) and
pMKO.1 puro shp53 (10672) were from Addgene. To generate pSuper.
retro.puro_shLUC (luciferase control), pSuper.retro.puro_shp53#2,
pSuper.retro.puro_shMOB2#4, and pSuper.retro.puro_shMOB2#6
vectors that express shRNAs against human p53 and hMOB2, the
following oligonucleotide pairs were inserted into pSuper.retro.puro
(Oligoengine) using BglII and HindIII: 5′-GATCCCCGTACGCGGAATACTT
CGATTCAAGAGATCGAAGTATTCCGCGTACGTTTTTGGAAA-3′ and 5′-
AGCTTTTCCAAAAACGTACGCGGAATACTTCG ATCTCTTGAATCGAAGTA
TTCCGCGTACGGG-3′ targeting ﬁreﬂy luciferase; 5′-GATCCCGACTCCAG
TGGTAATCTACTTCAAGAGAGTAGATTACCACTGGAGTCTTTTTGGAAA-3′
and 5′-AGCTTTTCCAAAAAGACTCCAGTGGTAATCTACTCTCTTGAAGT
AGATTACCACTGGAGTCGG-3′ for targeting p53; 5′-GATCCCGGAG
AGACGTGTCAGACGATTCAAGAGATCGTCTGACACGTCTCTCCTTTTTGG
AAA-3′ and 5′-AGCTTTTCCAAAAAGGAGAGACGTGTCAGACGATCTCTTG
AATCGTCTGACACG TCTCTCCGG-3′, or 5′-GATCCCGCGTGCCGTTTGTA
GAGAGTTCAAGAG ACTCTCTACAAACGGCACGCTTTTTGGAAA-3′ and 5′-
AGCTTTTCCAAAAAG CGTGCCGTTTGTAGAGAGTCTCTTGAACTCTCTACA
AACGGCACGCGG-3′ for targeting hMOB2. For siRNA rescue experi-
ments, HA-tagged hMOB2 cDNA was subcloned into pLXSN (Clontech)
using HpaI and XhoI. All constructs were conﬁrmed by sequence analy-
sis. Further details of the generation of constructs and sequences of
primers are available upon request.
2.11. RNA isolation, cDNA synthesis, and real-time quantitative PCR gene
expression analysis
Total RNA was extracted using Trizol Reagent (Life Technologies)
following the manufacturer's protocol. RNA concentration and integrity
was determined using a NanoDrop 1000 spectrophotometer (Thermo
Scientiﬁc). cDNA synthesis was performed using iScript One-Step
RT-PCR Kit (Bio-Rad). qPCR was carried out using validated qPCR
primers (Qiagen) and the QuantiTect SYBR Green PCR Kit (Bio-Rad)
using the Mastercycler ep realplex (Eppendorf). 18S rRNA served as in-
ternal control for standardisation.
2.12. Statistical analysis
Graphics and statistical analyses were carried out using the
GraphPad Prism software. Data are presented as mean ± s.e.m., unless
stated otherwise. The signiﬁcance of differences between the means
or the population distributions was determined using the two-way
ANOVA test (for proliferation analysis), or one-tailed unpaired Student's
t-test (for RTqPCR, γH2A.X/53BP1, comet experiments, clonogenicFig. 4. hMOB2 depletion results in a p53-dependent G1/S cell cycle arrest. (A) Immunoblottin
(+Tet) or without (−Tet) tetracycline as indicated. (B) Quantitative real time PCR analysis of in
ence (black bars) or absence (gray bars) of tetracycline (n=3). P-values are: p21, 72 h=5.5E−
1.7E−03, 96 h=4.4E−03; GADD45, 96 h=0.026; BAX, 72h=0.047; TIGAR, 72h=0.025. (C
siRNA-resistant hMOB2 (pLXSN-HA-hMOB2) transfectedwith indicated siRNAs (CTL, control; #
lysates from cells infectedwith indicated plasmids. Cell poolswere analysed after 4 dayswith (+
were analysed in the presence (+Tet) or absence (−Tet) of tetracycline (n=3). (F) Cell cycle a
Percentages of cells in each cell cycle phase are shown (n = 3).
Please cite this article as: V. Gomez, et al., Cell. Signal. (2014), http://dx.dosurvival assays, and G1/S cell cycle checkpoint experiments). For all
tests, differences were considered statistically signiﬁcant when P values
were below 0.05 (*), 0.01 (**), or 0.001 (***), respectively. P-values are
indicated in the corresponding ﬁgure legends.
3. Results
3.1. hMOB2 promotes cell survival and G1/S cell cycle arrest after DNA
damage induction
Since hMOB2 (HCCA2)might represent a novel DDRprotein [24],we
tested whether hMOB2 is required for cell survival of cells after expo-
sure to DNA damage. We employed U2-OS cells, as they are routinely
used for clonogenic cell survival assays in the context of DNA damaging
agents [39]. To induce DNA damage exogenously, cells were treated
with doxorubicin or ionising radiation (IR), both of which can induce
DNAdouble strandbreak (DSB) and are routinely used in chemotherapy
regimens [40]. To circumvent effects due to possibly altered cell cycle
progression, we employed acute (1 h) doxorubicin treatments of cells
24 h after siRNA transfection (Fig. 1A). hMOB2 depletion caused signif-
icantly increased drug- and radio-sensitivities (Fig. 1B and C), revealing
that hMOB2 contributes to cell survival following exposure to doxorubi-
cin or IR. The results reported in the genome wide DDR screen [24]
proposed that hMOB2 contributes to mitomycin C sensitivity. In full
support of this screening result [24], we observed that depletion of
hMOB2 in U2-OS cells also causes increased sensitivity to the chemo-
therapeutic agent mitomycin C (data not shown). Taken together,
these ﬁndings suggest that hMOB2 knockdown is sufﬁcient to cause in-
creased sensitivities towards three commonly used DNA damaging
therapeutics.
Elledge and colleagues further showed in their DDR screen that
hMOB2 knockdown cells have impaired activation of the IR-induced
G2/M cell cycle checkpoint [24]. We therefore asked whether other
DDR cell cycle checkpoints are also dependent on hMOB2. To address
the p53-regulated G1/S checkpoint we chose to employ a previously re-
ported approach using untransformed human MCF10A cells [41].
MCF10A cells were chronically (stably) depleted of hMOB2, p53 or
both together (Fig. 1D). DDR-mediated cell cycle perturbations were
assessed at selected time points after treatment and washout of indicat-
ed doxorubicin doses (Fig. 1E and F). As expected [42], control cells
arrested mainly at the G1/S and G2/M cell cycle phases, while p53-
depleted cells arrested only at the G2/M checkpoint. hMOB2-depleted
cells initially arrested at G1/S similar to controls. Upon washout of
100 nM doxorubicin, controls and hMOB2-depleted cells rapidly
resumed cell cycle progression. However, upon washout of 500 nM
doxorubicin hMOB2-depleted cells quickly resumed G1/S cell cycle pro-
gression in contrast to controls (Fig. 1F, bottom panel), indicating a de-
fective G1/S checkpoint in hMOB2-depleted cells upon exposure to
high DNA damage levels. Collectively, these ﬁndings together with the
data by Cotta-Ramusino et al. [24] suggest that upon exogenously in-
duced DNA damage hMOB2 functions in promoting cell survival and
cell cycle checkpoints, two hallmarks of the DDR.
3.2. hMOB2 is required for normal ATM–NBS1–SMC1 signalling in the DDR
Next, we addressed a third hallmark of the DDR in the context of
hMOB2 manipulation. In response to DNA damage, the MRN DNAg with indicated antibodies of RPE1 Tet-on shMOB2 cell lysates from cells incubated with
dicated p53 target genes in RPE1 Tet-on shMOB2 cells at indicated time points in the pres-
03, 96 h=5.2E−05;MDM2, 72h=1.3E−03, 96 h=0.018; PUMA, 48 h=0.033, 72 h=
) Immunoblotting of RPE1 cell lysates from cells stably expressing empty vector (pLXSN) or
6, siRNA targeting the 3′UTR of hMOB2). (D) Immunoblotting of RPE1 Tet-on shMOB2 cell
Tet) orwithout (−Tet) tetracycline. (E) Cell proliferation rates of cell pools described inD
nalyses of cell pools after 4 days in the presence (+Tet) or absence (−Tet) of tetracycline.
i.org/10.1016/j.cellsig.2014.11.016
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bind rapidly to damaged DNA in order to activate a co-ordinated pro-
gramme of events [43], which involves MRN-mediated recruitment ofPlease cite this article as: V. Gomez, et al., Cell. Signal. (2014), http://dx.dothe ataxia-telangiectasia mutated (ATM) kinase to DSBs [26–28]. Once
activated by autophosphorylation [44], the central DDR protein kinase
ATM phosphorylates many substrates involved in DDR signalling [45].i.org/10.1016/j.cellsig.2014.11.016
9V. Gomez et al. / Cellular Signalling xxx (2014) xxx–xxxActivated ATM phosphorylates effectors, such as p53, CHK2, and KAP1,
as well as the MRN component NBS1 to create a positive feedback
loop maintaining ATM activity [45]. ATM further phosphorylates
SMC1, an event required for cell survival in response to DNA damage
[46–48]. Therefore, to study these multiple branches of DDR signalling,
IR-induced phosphorylation of ATM and a panel of ATM substrates
were compared between controls and hMOB2-knockdown cells 24 h
post siRNA transfections (Fig. 2A and B). Intriguingly, this analysis re-
vealed that the IR-induced phosphorylation levels of ATM, SMC1 and
NBS1 were signiﬁcantly altered in hMOB2-depleted cells, while p53,
CHK2, and KAP1 phosphorylation was unaffected when compared to
controls (Fig. 2A and B). This indicates that hMOB2 is dispensable for
some ATM activities, while being required for optimal ATM activation
and ATM-mediated phosphorylation of NBS1 and SMC1. Thus, given
that hMOB2 is needed for some aspects of DDR signalling, hMOB2 dis-
plays another hallmark of a DDR protein. Collectively, our results pro-
pose that hMOB2 supports the DDR, since upon DNA damage
induction three different hallmarks of the DDR, namely cell survival,
cell cycle checkpoint activation, and DDR signalling are impaired in
hMOB2-depleted cells.3.3. hMOB2 is needed to prevent a transient p53/p21-dependent G1/S cell
cycle arrest
As the phenotypes described in Figs. 1 and 2 were based on exoge-
nously induced DNA damage, we sought to complement our analysis
by examining the role of endogenous hMOB2 in untransformed
human cells under normal growth conditions in the absence of exoge-
nously induced DNA damage. Given that cell survival in response to
DNA damage relies on proper cell cycle control, we focused on investi-
gating hMOB2 in cell cycle progression. This unbiased approach is cru-
cial, since some essential DDR regulators are cell cycle regulated
which can complicate the analyses of cellular and molecular DDR phe-
notypes. For example, MRN protein, but not mRNA, levels are cell
cycle regulated [49], hence any study relating to MRN functionality
that does not take cell cycle progression into account is likely to exam-
ine amix of direct and indirect effects. To ensure that our work does not
suffer from such shortcomings, we engineered [30] untransformed
human RPE1 cells with tetracycline-inducible (Tet-on) hMOB2 deple-
tion in order to study cell cycle progression in consistent knockdown
conditions. Signiﬁcantly, hMOB2 depletion increased the levels of the
G1/Smarkers cyclin D1 and E, while decreasing the S/G2/Mmarkers cy-
clin A and B1 (Fig. 3A). These changes in cyclin expression were accom-
panied by impaired cell proliferation upon hMOB2 silencing (Fig. 3B).
Analyses of cell cycle proﬁles revealed that hMOB2-depleted cells
displayed a G1/S cell cycle arrest (Fig. 3C). The stable Tet-on system
also allowed us to deplete hMOB2 in serum starved cells, prior to addi-
tion of serum in order to synchronously release cells from G0/G1 into
S-phase. Notably, this approach revealed that synchronised hMOB2-
silenced cells displayed a markedly delayed G1/S cell cycle transition
(Fig. 3D–F). Collectively, these ﬁndings indicate that endogenous
hMOB2 is required for normal cell cycle progression.
To deﬁne the underlying molecular basis of the G1/S arrest upon
hMOB2 depletion, we expanded our analysis of cell cycle regulators
(Fig. 4A). We observed activation of the p53–pRB axis [42] through
p53 stabilisation and decreased pRB phosphorylation followingFig. 5. In normal growth conditions hMOB2-depleted cells accumulate unrepaired DNA damag
lysates from cells incubated with (+Tet) or without (−Tet) tetracycline for indicated times. C
and BJ cell lysates from cells transiently transfected with indicated siRNAs. (D) Immunodetectio
(+Tet) or absence (−Tet) of tetracycline for 96 h. DNA is stained blue. (E) Histograms showing
double positive 53BP1/γH2AX DSB foci per nuclei were counted as DSB positive (1000 cell
(F) Immunodetection of 53BP1 (green) and γH2AX (red) in RPE1 Tet-on shMOB2 cells cultur
96 h. (G) Histograms showing percentages of cells with DSBs in the absence of serum. Cells
from cells serum-starved for 72 h with (+Tet) or without (−Tet) tetracycline, before addition
of DNA breaks by comet assays in RPE1 Tet-on shMOB2 cells treatedwith (+Tet) orwithout (−
shMOB2 cells at indicated time points (n = 3). P-values are: 48 h = 2.67E−03; 72 h = 1.69E
Please cite this article as: V. Gomez, et al., Cell. Signal. (2014), http://dx.dohMOB2 knockdown (Fig. 4A). Furthermore, p21/Cip1 and Mdm2, two
established p53 target genes [50], were elevated at the protein and
mRNA levels (Fig. 4A and B). Expression of other p53 target genes was
also signiﬁcantly enhanced (Fig. 4B and Supplementary Fig. S1A).
These ﬁndings indicate that transcriptionally active p53 is stabilised
upon MOB2 silencing. Transfections of three different untransformed
human cell lines with three independent siRNAs directed against
hMOB2 consistently elevated p53 levels (Supplementary Fig. S1B). Ex-
pression of siRNA-resistant hMOB2 interfered with p53 induction
upon MOB2 depletion (Fig. 4C), hence rescuing the phenotype caused
by RNAi-mediated silencing of hMOB2. Taken together, these ap-
proaches rule out the possibility that the stabilisation of active p53
upon hMOB2 depletion is a consequence of RNAi off-target effects.
Sustained p53 stabilisation results in a permanent proliferation ar-
rest through senescence, while pulses of stabilised p53 yield a transient
cell cycle arrest [51]. Using increased cell size as senescencemarker [52],
we found that hMOB2 knockdown does not cause senescence in RPE1
cells (data not shown). Our data rather suggest that hMOB2 silencing
triggers a transient p53-dependent arrest, since co-depletion of
hMOB2 together with p53 restored normal cell proliferation, abolishing
the G1/S cell cycle arrest (Fig. 4D–F). Co-depletion of hMOB2 and p21
resulted in a similar restoration of cell cycle progression in spite of in-
creased p53 levels (Supplementary Fig. S2). Therefore, p53-mediated
upregulation of p21 likely underlies the G1/S cell cycle arrest observed
upon hMOB2 reduction under normal growth conditions in the absence
of exogenously induced DNA damage.3.4. hMOB2 depletion triggers a DNA damage–ATM–CHK2–p53–p21
cascade
Given that the p53–p21 pathway is a master regulator of the G1/S
cell cycle transition in the DDR [50], we were prompted to examine
p53 in the context of DDR signalling in hMOB2-depleted cells under
normal growth conditions. We hypothesised that a DDR defect due to
hMOB2 knockdown could explainwhy hMOB2-depleted cells displayed
a p53-dependent G1/S cell cycle arrest. Possibly hMOB2-depleted cells
accumulate unrepaired DNA damage, which can trigger p53 activation.
Signiﬁcantly, upon hMOB2 depletion increased p53 protein levels did
not correlate with changes in p53 mRNA expression (Fig. 4A and
Supplementary Fig. S1A), while p53 phosphorylation on Ser15 did
(Fig. 5A), revealing a possible stabilisation mechanism of p53 [50].
CHK2 phosphorylation on Thr68 was also augmented (Fig. 5B), indicat-
ing elevated ATM activity upon hMOB2 knockdown under normal
growth conditions. hMOB2 depletion in untransformed human BJ and
MCF10A cells by an independent siRNA also triggered DDR signalling
as judged by elevated CHK2 and p53 phosphorylation (Fig. 5C).
To probewhether DDR signallingwas increased as a consequence of
elevated DNA damage levels, we next examined DSB formation by co-
labelling for the DNA repair mediators γH2AX and 53BP1 (Fig. 5D), re-
vealing that the number of cells with more than ﬁve DSBs per cell in-
creased three-fold upon MOB2 silencing (Fig. 5E). The accumulation of
DSBs was proliferation dependent, as hMOB2 depletion had no effect
in non-cycling cells (Fig. 5F and G). Proliferating hMOB2-depleted
cells displayed activation of ATM–CHK2–p53–p21 signalling, while con-
trols and serum-starved cells did not (Fig. 5H), indicating that hMOB2
depletion triggers activation of the ATM–p53–p21 cascade. Next, wee, triggering ATM–p53–p21 signalling. (A, B) Immunoblotting of RPE1 Tet-on shMOB2 cell
ontrols were incubated with doxorubicin (+Dox). (C) Immunoblotting of RPE1, MCF10A,
n of 53BP1 (green) and γH2AX (red) in RPE1 Tet-on shMOB2 cells grown in the presence
percentages of cells with DSBs in the presence of serum. Only cells displaying at least (≥) 5
s per time point in control (grey) or hMOB2-depleted (black) cells (P-value = 0.006).
ed in the presence (+Tet) or absence (−Tet) of tetracycline without serum (0% FCS) for
were scored as described in E. (H) Immunoblotting of RPE1 Tet-on shMOB2 cell lysates
of medium without (0% FBS) or with serum (10% FBS) for another 72 h. (I) Measurement
Tet) tetracycline for 96 h. (J) Quantiﬁcation of DNA damage by comet assay in RPE1 Tet-on
−05; 96 h = 2.23E−20. IR at 15Gy served as positive control.
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Fig. 7. hMOB2 interacts with the MRN component RAD50, regulating MRN–ATM recruitment to DNA damaged chromatin. (A) List of novel hMOB2 binding partners identiﬁed at least
twice by yeast two-hybrid (Y2H) screens. The number of independent hits is indicated. (B) RPE1 Tet-on shMOB2 cells incubated with (+Tet) or without (−Tet) tetracycline for 96 h
were subjected to immunoprecipitation (IP) using anti-RAD50 (RAD50) or control (IgG) antibodies, before inputs and immunoprecipitates were analysed by immunoblotting. Asterisk
(*) marks an unspeciﬁc band in the RAD50 blot. (C) COS-7 lysates transiently expressing indicated combinations of HA-tagged RAD50 and myc-tagged hMOB2 were subjected to immu-
noprecipitation using anti-HA 12CA5 antibody, before immunoblotting of immuno-complexes and input lysates. (D) Primary structure of RAD50 indicating direct hMOB2 binding sites
deﬁned by Y2Hmapping. Known functional domains of RAD50 are highlighted. (E) RPE1 cells transiently transfected for 24 h with indicated siRNAs (−, siCTL; +, siMOB2) were treated
with indicated doxorubicin doses, before separation into chromatin and cytosolic fractions, and subsequent immunoblotting with indicated antibodies.
11V. Gomez et al. / Cellular Signalling xxx (2014) xxx–xxxperformed comet assays to measure DNA breakage directly, revealing
that upon hMOB2 depletion cells rapidly accumulate DNA breaks
(Fig. 5I and J). Signiﬁcantly, this analysis further showed that in
hMOB2-depleted cells DNA breakage was elevated before DSBs were
detectable by immunoﬂuorescence (compare Fig. 5E and J). Since
γH2AX/53BP1 accumulates at DSBs only after DDR activation [43],
these ﬁndings indicate that DNA lesions precede DDR activation in
hMOB2-depleted cells. Collectively, these data show that hMOB2 is re-
quired to prevent the accumulation of unrepaired DNA damage. Once
hMOB2 levels are decreased, unrepaired DNA damage accumulates,
triggering DNA damage-p53 signalling, which elevates p21 expression
to arrest cells at the G1/S cell cycle checkpoint.
3.5. Neither NDR manipulations nor hMOB2 overexpression halt cell
cycle progression
p53 stabilisation/activation can occur via a variety of distinct mech-
anisms [50]. Considering that NDR is the only reported binding partnerFig. 6. NDR signalling is not required for cell cycle progression of RPE1 cells. (A) Immunoblotti
(−Tet) tetracycline for indicated times. (B) Proliferation rates of RPE1 Tet-on HA-NDR1-PIF cel
ence (+Tet) or absence (−Tet) of tetracycline (n=3). (D) Immunoblotting of RPE1 Tet-on shN
(n= 3). (F) Cell cycle analyses of RPE1 Tet-on shNDR1#4 cells after 96 h in the presence (+Tet
cells transfected with indicated siRNAs (CTL, control; #5, siNDR2). Asterisk (*) in NDR2 blot ma
analyses of RPE1 cells 96 h after indicated siRNA transfections (n = 3).
Please cite this article as: V. Gomez, et al., Cell. Signal. (2014), http://dx.doof hMOB2 [1], we interrogated NDR signalling as a possible mechanism.
We speculated that hMOB2 depletion might cause hypo- or hyper-
activation of NDR signalling which potentially could help us to under-
stand how hMOB2 depletion triggers a p53-dependent G1/S cell cycle
arrest. To study the importance of NDR signalling in our settings, we
pursued three different avenues. First, we generated and subsequently
analysed cells with Tet-on inducible overexpression of constitutively
hyperactive NDR1-PIF [38] to mimic possible hyperactivation of NDR
upon hMOB2 depletion (Fig. 6A–C). Second, NDR1 and NDR2 kinases
were depleted to mimic possible hypoactivation of NDR signalling in
our settings (Fig. 6D–I). Third, we generated cells with Tet-on inducible
overexpression of hMOB2 (Supplementary Fig. S3) to test whether
hMOB2 functioning as an inhibitor of NDR kinases [18] plays a role
in cell cycle progression. Unexpectedly, neither overexpression of
hyperactive NDR1 nor NDR depletions negatively affected cell prolifera-
tion (Fig. 6). Moreover, hMOB2 overexpression did not alter cell prolif-
eration (Supplementary Fig. S3). Therefore, we concluded that NDR
signalling is not essential for p53-regulated proliferation ofng of RPE1 Tet-on HA-NDR1-PIF cell lysates from cells incubated with (+Tet) or without
ls (n = 3). (C) Cell cycle analyses of RPE1 Tet-on HA-NDR1-PIF cells after 96 h in the pres-
DR1#4 cell lysates as described in A. (E) Proliferation rates of RPE1 Tet-on shNDR1#4 cells
) or absence (−Tet) of tetracycline (n= 3). (G) Immunoblotting of RPE1 cell lysates from
rks an unspeciﬁc band. (H) Proliferation rates of indicated cell lines (n = 3). (I) Cell cycle
i.org/10.1016/j.cellsig.2014.11.016
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the ﬁndings described in Figs. 3 and 4, these observations further indi-
cate that endogenous hMOB2 is required for normal cell cycle progres-
sion independent of NDR kinase signalling.
3.6. hMOB2 interacts with RAD50, regulating MRN–ATM recruitment to
DNA damaged chromatin
To uncover how hMOB2 can function as a DDR protein, we
performed yeast two hybrid (Y2H) screens with full-length hMOB2 as
a bait, aiming to identify novel direct (binary) binding partners of
hMOB2 that are linked to DDR signalling (Supplementary Table S1).
Signiﬁcantly, this screen revealed UBR5 and RAD50, two known DDR
proteins, as top candidates (Fig. 7A). The HECT domain E3 ligase UBR5
(also termed EDD1) was the most frequently isolated prey (Fig. 7A
and Supplementary Table S1). However, all hits for UBR5 were not in
frame with the GAL4 activation domain (Supplementary Table S1),
and the interaction between hMOB2 and UBR5 was undetectable by
co-immunoprecipitation experiments upon overexpression inmamma-
lian cells (Supplementary Fig. S4). This indicates that the observed Y2H
interaction between hMOB2 and UBR5 is very likely an Y2H artefact.
Furthermore, UBR5 knockdown affects IR-induced KAP1 phosphoryla-
tion, without altering ATM autophosphorylation [53], and impairs
DNA damage-induced CHK2 phosphorylation [54]. Moreover, UBR5
overexpression inhibits p53 phosphorylation by ATM [55]. Therefore,
as IR-induced KAP1, CHK2, and p53 phosphorylation were unaffected
in hMOB2-depleted cells (Fig. 2), it is very unlikely that hMOB2 is rele-
vant for UBR5 function.
Consequently, we focused on understanding the interaction be-
tween hMOB2 and RAD50, which was repeatedly observed by Y2H
(Fig. 7A). RAD50 is a key component of the MRN complex, which is re-
quired from DNA damage detection to triggering DDR signalling, subse-
quently activating cell cycle checkpoints and DNA repair pathways
[26–28]. Thus, the identiﬁcation of novel MRN regulators has insightful
implications for our understanding of the DDR in human cell biology
[25]. Moreover, a link between hMOB2 andMRN function could explain
why hMOB2-depleted cells display heightened sensitivity to DNA dam-
aging agents, impaired DDR signalling, defective cell cycle checkpoints,
accumulation of unrepaired DNA damage, and a cell cycle progression
defect. We ﬁrst aimed to conﬁrm the interaction of hMOB2 with
RAD50 in mammalian cells. In contrast to our ﬁndings with regard to
UBR5 (see Supplementary Fig. S4), co-immunoprecipitation experi-
ments using mammalian cell lysates readily detected the formation of
hMOB2/RAD50 complexes on endogenous and exogenous levels
(Fig. 7B and C). Furthermore, Y2H mapping deﬁned the region sur-
rounding the zinc hook domain and a C-terminal stretch encompassing
part of the ABC domain of RAD50 as binary binding sites for hMOB2
(Fig. 7D).
Given this novel and unexpected link between hMOB2 and MRN
through the hMOB2/RAD50 interaction, we wondered whether
hMOB2 contributes to DNA damage induced chromatin binding of
MRN and subsequent ATM recruitment, which is crucial for efﬁcient
MRN-mediated ATM signalling [26–28]. To avoid indirect cell cycle ef-
fects in our analysis of MRN functionality, we examined cells 24 h
after siRNA transfection, since at this time point neither MRN was de-
creased nor p53 levels were increased despite efﬁcient hMOB2 deple-
tion (Supplementary Fig. S5). To induce DNA damage exogenously,
cells were treated with doxorubicin, before cells were subjected to
chromatin–cytosol fractionations, followed by immunoblotting of
MRN to detect DNA damage-induced enrichment at chromatin. Signiﬁ-
cantly, this analysis revealed that hMOB2 is required for normal MRN
recruitment to DNA damaged chromatin, since DNA damage-induced
enrichment of MRN at chromatin was severely impaired upon hMOB2
depletion (Fig. 7E). In addition, enrichment of activated ATM at DNA
damaged chromatin was also dependent on hMOB2 (Fig. 7E, top
panel). Similar results were obtained when hMOB2 was depleted byPlease cite this article as: V. Gomez, et al., Cell. Signal. (2014), http://dx.doan independent shRNA using RPE1 Tet-on shMOB2 cells (data not
shown). Taken together, these ﬁndings indicate that hMOB2 supports
the recruitment ofMRN and activated ATM toDNAdamaged chromatin,
hence providing the ﬁrst mechanistic insight into how hMOB2 can con-
tribute to optimal ATM activation and ATM substrate phosphorylation.
4. Discussion
We describe herein novel functions of hMOB2 in the DDR and cell
cycle regulation. Like MRN deﬁcient cells [26–28], hMOB2-depleted
cells display impaired cell proliferation, heightened sensitivity to DNA
damaging agents, defective cell cycle checkpoints, and suboptimal
ATM activation. Therefore, our data cumulatively suggest that hMOB2
supportsMRN functionality, which is crucial for DNA damage detection,
DDR signalling, and cell cycle checkpoint activation, consequently pro-
moting efﬁcient DNA repair. Hypothetically, impaired ATM activation
could result from ATMIN deﬁciency, another ATM activator [56].
However, unlike ATMIN deﬁciency [56], hMOB2 depletion decreased
IR-induced SMC1 phosphorylation and increased radiosensitivity, indi-
cating hMOB2 knockdown does not phenocopy ATMIN deﬁciency. Our
data rather advocate that MRN functionality is impaired in hMOB2-
depleted cells, since MRN retention at DNA damaged chromatin is de-
fective, MRN-mediated recruitment of activated ATM to DNA damaged
chromatin is reduced, hence IR-induced ATM activation is impaired,
and ATM-mediated NBS1 and SMC1 phosphorylation decreases. Collec-
tively, our data show that hMOB2 depletion mimics certain aspects of
MRN deﬁciency on the molecular and cellular level.
Our data provide the ﬁrst mechanistic insight into how hMOB2 can
function in the DDR by suggesting that hMOB2 contributes to the DDR
on at least two molecular levels. On the one hand, hMOB2 contributes
to MRN-mediated recruitment of activated ATM to DNA damaged chro-
matin. On the other hand, hMOB2 seems to support MRN as an adaptor
for ATM substrates such as SMC1, while hMOB2 is dispensable for
IR-induced ATM-mediated phosphorylation of p53 and CHK2. These
ﬁndings suggest that hMOB2 is required to promoteMRN-mediated sig-
nalling events, while hMOB2 is expendable for MRN-independent ATM
signalling. This interpretation is in full agreement with published re-
ports showing that SMC1 phosphorylation by ATM is MRN-dependent
[46–48] and defective ATM activation is quantitative, not absolute, in
MRN mutant cells [47,57–59], while MRN-mediated ATM activation is
dispensable for CHK2 and p53 phosphorylation [60,61]. Moreover, our
data suggest that the observed suboptimal activation of ATM is a conse-
quence of impaired MRN functionality due to hMOB2 depletion. This
conclusion is fully supported by previous reports demonstrating that
the positive feedback loopmaintaining optimal ATMactivation requires
MRN-mediated ATM recruitment to damaged DNA [45]. Decreased
ATM-mediated SMC1 and NBS1 phosphorylation could result from
defective MRN-ATM recruitment to DNA damaged chromatin upon
hMOB2 depletion. Conversely, these signalling events could represent
separate, but interlinked,MRN functions supported by hMOB2. Possibly,
hMOB2 is also required for efﬁcient ATM phosphorylation of other sub-
strates, besides NBS1 and SMC1, since ATM has potentially more than
700 substrates [45]. Therefore, since MRN exists in diverse conforma-
tional and assembly states [26,28], future structural and biochemical
studies are warranted to further dissect hMOB2 as facilitator of MRN
recruitment toDNAdamaged chromatin and as an adaptor for ATMsub-
strates. Particular attentionwill be paid to dissecting the RAD50/hMOB2
interaction in the context of our Y2H mapping data and the unique ar-
chitecture of RAD50, which is essential to support MRE11/RAD50 bind-
ing to DNA via MRE11's DNA bindingmotifs and RAD50's ABC domains,
while DNA break tethering is achieved through RAD50's zinc hook do-
main supported by RAD50's coiled-coil structure [26–28].
MRN is also required for balanced DSB repair [26–28]. Misbalance
between DNA damage and repair results in higher p53 levels through
pulses [62], causing a transient p53-dependent G1/S cell cycle arrest
[51]. Similarly, under normal growth conditions in the absence ofi.org/10.1016/j.cellsig.2014.11.016
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unrepaired DNA damage, triggering a p53-dependent G1/S cell cycle ar-
rest. Thus, our ﬁndings collectively suggest that the roles of hMOB2 in
the DDR and cell cycle progression are interlinked, proposing the fol-
lowingworkingmodel for normal growth conditions: generally, low en-
dogenous DNA damage (as normally caused by reactive oxygen species,
DNA replication, and other mechanisms [63]) is sensed by the MRN to
coordinate the necessary DDR steps. In contrast, hMOB2-depletion
impairs MRN recruitment to DNA damaged chromatin. Consequently
endogenous DNA damage is detected inefﬁciently, causing accumula-
tion of DNA damage, which triggers a p53-dependent G1/S arrest in
hMOB2-depleted cells under normal growth conditions without exoge-
nously induced DNA damage.
Upon exposure to high levels of exogenously induced DNA damage
hMOB2 is further needed to promote activation of the G1/S and G2/M
cell cycle checkpoints. We report here a defective G1/S checkpoint in
hMOB2-depleted cells upon exposure to high DNA damage levels, and
Cotta-Ramusino et al. showed that hMOB2-depleted cells have impaired
activation of the IR-induced G2/M cell cycle checkpoint [24]. Most likely,
these DDR cell cycle checkpoint defects are a result of impaired MRN
functionality upon hMOB2 depletion, since we show here that hMOB2
is needed to support MRN functionality and MRN deﬁciencies are
known toweaken the G1/S and G2/M cell cycle checkpoints [26–28]. No-
tably, given that cell survival in response to DNAdamage relies on proper
cell cycle control, these cell cycle checkpoint interpretations can also help
to explain why hMOB2 contributes to cell survival upon exposure to dif-
ferent DNA damaging agents. Nevertheless, we have only begun to un-
derstand how hMOB2 promotes cell survival and cell cycle checkpoint
activation upon exposure to DNA damage, hence future studies into the
regulation andwiring of cell cycle checkpoints by hMOB2 are warranted.
The humanMOB2 gene appears to display LOH in more than 50% of
bladder, cervical and ovarian carcinomas (TCGA) [21], hence, hMOB2
might represent a novel tumour suppressor promoting the DDR re-
sponse. Future studies are therefore warranted to explore in yet to be
developed animal models the consequences of MOB2 deﬁciency for tu-
mour formation and the response to DNAdamaging treatments. Consid-
ering that at least 30% of cancer cell lines [21] seem to display LOH of the
MOB2 gene, tissue culture approaches may be able to initially comple-
ment these upcoming experiments. Although hMOB2 is unlikely to
serve as good drug target, future studies are also needed to investigate
whether hMOB2 expression may offer a means to stratify patients for
DNA damaging therapies, with the aim of potentially reducing the fre-
quency of cancer therapy resistance [64], in addition to further
expanding our understanding of the role of hMOB2 in human cell biol-
ogy and disease.5. Conclusions
In summary, our study provides, for the ﬁrst time, evidence suggest-
ing that hMOB2 is a novel DDR protein. In normal growth conditions
hMOB2 is required to prevent the accumulation of unrepaired DNA
damage. Upon exposure to high levels of exogenously induced DNA
damage hMOB2 supports cell survival, cell cycle checkpoint activation,
and DDR signalling. Surprisingly, these novel functions of hMOB2
appear to be independent of NDR signalling, but rather seem to be de-
pendent on a link between hMOB2 and the MRN DNA damage sensor
complex, since hMOB2 supports the recruitment of MRN and activated
ATM to DNA damaged chromatin. Consequently, we provide novel in-
sights into signalling functions of hMOB2 that possibly are critical in
human diseases linked to DDR defects.Conﬂict of interest
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